Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.
Saved in:
| Title: | Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. |
|---|---|
| Authors: | Natali A; Department of Clinical and Experimental Medicine, Pisa University, Via Savi 27, 56100, Pisa, Italy., Nesti L; Department of Clinical and Experimental Medicine, Pisa University, Via Savi 27, 56100, Pisa, Italy. lorenzonesti90@gmail.com., Fabiani I; Department of Surgery, Medical, Molecular, and Critical Area Pathology, Pisa University, Pisa, Italy., Calogero E; Department of Surgery, Medical, Molecular, and Critical Area Pathology, Pisa University, Pisa, Italy., Di Bello V; Department of Surgery, Medical, Molecular, and Critical Area Pathology, Pisa University, Pisa, Italy. |
| Source: | Cardiovascular diabetology [Cardiovasc Diabetol] 2017 Oct 12; Vol. 16 (1), pp. 130. Date of Electronic Publication: 2017 Oct 12. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1475-2840 |
|---|---|
| DOI: | 10.1186/s12933-017-0615-6 |
